Meteorin-like Levels in Individuals With Periodontitis

Healthy Clinical Trial

Official title:

Evaluation of Meteorin-like Levels in Individuals With Healthy and Periodontal Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04402996
• Other study ID #: Saglik Bilimleri Üniversitesi
• Status: Completed
• Start date: September 23, 2020
• Est. completion date: March 3, 2021

Study information

• Verified date: April 2024
• Source: Istanbul Saglik Bilimleri University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Metrnl has proven to be an inflammatory-related immunoregulatory cytokine and shown to play a role in the pathogenesis of human inflammatory diseases. Metrnl is highly expressed from the oral mucosa to the esophagus. Periodontitis is a chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. The authors think that Metrnl may play a role in the periodontitis. The aim of this study is to compare the Metrnl, IL-1β, and IL-10 levels of healthy and periodontitis individuals.

Description:

Periodontitis is a destructive chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. Cytokines play an important role in inflammation that occurs in periodontal disease.

Interleukine -1β ( IL-1β ) levels are associated with periodontal destruction in the pathogenesis of periodontal disease. Cytokines such as Interleukine-10 (IL-10) and transforming growth factor- β (TGF-β) have been reported to decrease periodontal disease progression rate.

Gingival crevicular fluid shows the cellular response in the periodontium. The most important host-related ingredients are inflammatory markers, including cytokines, enzymes, and interleukins. Saliva analysis is used in the diagnosis of systemic conditions as well as in the diagnosis of oral pathologies.

Meteorin- like (Metrnl) is a protein that plays a role in natural and acquired immune-related functions and inflammatory responses, and expressed in barrier tissues (skin and mucosa) as well as various macrophage populations, from dendritic cells and some granulocytes. Metrnl has proven to be an inflammatory-related immunoregulatory cytokine and shown to play a role in the pathogenesis of human inflammatory diseases. Metrnl, which is highly expressed from the oral mucosa to the esophagus, may play a role in the onset of periodontitis and an effective marker in preventing the progression of destruction. We think that Metrnl plays an important role in periodontitis, an inflammatory disease. The aim of this study is to compare the Metrnl, IL-1β, and IL-10 levels of healthy and periodontitis individuals

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 3, 2021
• Est. primary completion date: March 3, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• systemically healthy

• individuals who does not have a disease under treatment,

• individuals without regular systemic medication

Exclusion Criteria:

• smoking

• receiving periodontal treatment in the last 6 months

• pregnancy

• menopausal or menstrual period

Related Conditions & MeSH terms

• Gingivitis
• Healthy
• Periodontitis

Intervention

Other:
• Saliva
individuals' saliva samples will be collected and transferred to eppendorf tubes. Until biochemical analysis is carried out will be stored in -80ºC.
• gingival crevicular fluid
GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes. Until biochemical analysis is carried out will be stored in -80ºC.

Locations

Country	Name	City	State
Turkey	Ebru Saglam	Istanbul	Eyalet/Yerleske

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Saglik Bilimleri University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL-1ß	saliva and serum levels	through study completion, an average of 6 months
Primary	Metrnl	saliva and serum levels	through study completion, an average of 6 months
Primary	IL-10 levels	saliva and serum levels	through study completion, an average of 6 months
Secondary	Plaque Index	Silness-Löe	up to 20 weeks
Secondary	Probing Depth	millimeter	up to 20 weeks
Secondary	Bleeding on Probe	Ainamo&Bay	up to 20 weeks